Drug Profile


Alternative Names: 1278863; GSK-1278863; GSK-1278863A

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antianaemics; Pyrimidines; Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Prolyl hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia
  • Phase II Perioperative ischaemia
  • Phase I Diabetic foot ulcer; Tendon injuries
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 11 May 2017 Phase-III clinical trials in Anaemia in Spain (PO) (NCT03029208)
  • 10 Feb 2017 GlaxoSmithKline completes a phase I trial for Diabetic foot ulcer (In adults, In the elderly) in USA (Topical) (NCT01831804)
  • 01 Feb 2017 GlaxoSmithKline plans a phase III trial for Anaemia (PO, Tablet) (NCT03029208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top